View in EDS

Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical Trial.

Saved in:
Bibliographic Details
Title: Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical Trial.
Authors: Sehgal K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Thyroid Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Pappa T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Thyroid Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Shin KY; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Schiantarelli J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Liu M; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Ricker C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Besson NR; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Jones SM; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Welsh EL; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Pfaff KL; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Barletta JA; Harvard Medical School, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Park J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Reardon B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Doherty GM; Thyroid Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts., Alexander EK; Thyroid Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Rodig SJ; Harvard Medical School, Boston, Massachusetts.; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., O'Neill A; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Van Allen E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Haddad RI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Thyroid Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Lorch JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Thyroid Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts.; Head and Neck/Thyroid Program, Robert H. Lurie Cancer Center of Northwestern University, Chicago, Illinois.
Source: JAMA oncology [JAMA Oncol] 2024 Dec 01; Vol. 10 (12), pp. 1663-1671.
Publication Type: Journal Article; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39446365
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical Trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Sehgal+K%22">Sehgal K</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Thyroid Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Pappa+T%22">Pappa T</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Thyroid Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Shin+KY%22">Shin KY</searchLink>; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Schiantarelli+J%22">Schiantarelli J</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Liu+M%22">Liu M</searchLink>; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Ricker+C%22">Ricker C</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Besson+NR%22">Besson NR</searchLink>; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Jones+SM%22">Jones SM</searchLink>; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Welsh+EL%22">Welsh EL</searchLink>; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Pfaff+KL%22">Pfaff KL</searchLink>; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Barletta+JA%22">Barletta JA</searchLink>; Harvard Medical School, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Park+J%22">Park J</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Reardon+B%22">Reardon B</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Doherty+GM%22">Doherty GM</searchLink>; Thyroid Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Alexander+EK%22">Alexander EK</searchLink>; Thyroid Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Rodig+SJ%22">Rodig SJ</searchLink>; Harvard Medical School, Boston, Massachusetts.; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Barbie+DA%22">Barbie DA</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22O'Neill+A%22">O'Neill A</searchLink>; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Van+Allen+E%22">Van Allen E</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Haddad+RI%22">Haddad RI</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Thyroid Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Lorch+JH%22">Lorch JH</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Thyroid Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts.; Head and Neck/Thyroid Program, Robert H. Lurie Cancer Center of Northwestern University, Chicago, Illinois.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101652861%22">JAMA oncology</searchLink> [JAMA Oncol] 2024 Dec 01; Vol. 10 (12), pp. 1663-1671.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Medical+Association%22">American Medical Association </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101652861 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2374-2445 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223742437%22">23742437 </searchLink><i>NLM ISO Abbreviation: </i>JAMA Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39446365
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1001/jamaoncol.2024.4019
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1663
    Titles:
      – TitleFull: Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical Trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Sehgal K
      – PersonEntity:
          Name:
            NameFull: Pappa T
      – PersonEntity:
          Name:
            NameFull: Shin KY
      – PersonEntity:
          Name:
            NameFull: Schiantarelli J
      – PersonEntity:
          Name:
            NameFull: Liu M
      – PersonEntity:
          Name:
            NameFull: Ricker C
      – PersonEntity:
          Name:
            NameFull: Besson NR
      – PersonEntity:
          Name:
            NameFull: Jones SM
      – PersonEntity:
          Name:
            NameFull: Welsh EL
      – PersonEntity:
          Name:
            NameFull: Pfaff KL
      – PersonEntity:
          Name:
            NameFull: Barletta JA
      – PersonEntity:
          Name:
            NameFull: Park J
      – PersonEntity:
          Name:
            NameFull: Reardon B
      – PersonEntity:
          Name:
            NameFull: Doherty GM
      – PersonEntity:
          Name:
            NameFull: Alexander EK
      – PersonEntity:
          Name:
            NameFull: Rodig SJ
      – PersonEntity:
          Name:
            NameFull: Barbie DA
      – PersonEntity:
          Name:
            NameFull: O'Neill A
      – PersonEntity:
          Name:
            NameFull: Van Allen E
      – PersonEntity:
          Name:
            NameFull: Haddad RI
      – PersonEntity:
          Name:
            NameFull: Lorch JH
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2024 Dec 01
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 2374-2445
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: JAMA oncology
              Type: main
ResultId 1